d-lys(palmitoyl)-spermine
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2018 (NCT03536728)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Diffuse Intrinsic Pontine Glioma · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Thyroid Cancer, Papillary · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Mammalian polyamine transporterINHIBITOR
Mammalian polyamine transporter inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05500508 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2022 | Aminex Therapeutics, Inc. |
| NCT03536728 | Phase 1 | Jun 12, 2018 | Aminex Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aminex Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1